Article
The PIK3CA gene as a mutated target for cancer therapy.
Current cancer drug targets - 1 Dec 2008
Gustin John P, Cosgrove David P, Park Ben Ho
Abstract excerpt
The development of targeted therapies with true specificity for cancer relies upon exploiting differences between cancerous and normal cells. Genetic and genomic alterations including somatic mutations, translocations, and amplifications have served as recent examples of how such differences can be exploited as effective drug targets. Small molecule inhibitors and monoclonal antibodies directed against the...
Topics
- Class I Phosphatidylinositol 3-Kinases
- Enzyme Inhibitors
- Humans
- Mutation
- Neoplasms
- Phosphatidylinositol 3-Kinases
- Phosphoinositide-3 Kinase Inhibitors
- Protein Kinases
- Proto-Oncogene Proteins c-akt
- TOR Serine-Threonine Kinases